Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative science piloted at Johns Hopkins to the Group for further development. In conjunction with this, our faculty serve in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs.
The specific aims are: 1) to continue to provide scientific leadership in the disease-oriented committees: Breast, Thoracic, Head and Neck, Genitourinary, Brain Tumor Working Group, Lymphoma, Leukemia;2) to continue to expand our involvement in the disease and modality committees: Gastrointestinal, Myeloma, Pharmacology and Drug Development;to bring translational research correlates, cell biology and molecular biology into clinical protocols for all stages of disease;4) to continue to expand accrual, and to maintain excellent performance in data quality. These goals will be accomplished through the mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: to provide a multidisciplinary approach to the study of cancer that will result in improved means for prevention, diagnosis, and treatment. The Center has achieved excellence in translational research with the awarding of seven SPORE grants (cervix, lymphoma, G-l cancer, prostate, breast, lung, head and neck). In addition, early clinical trials of new drugs are conducted under the NCI phase I contract (since 1982). The Early Therapeutics Development with Phase II Emphasis grants allow the development of novel phase II and phase III concepts which the Cancer Center faculty bring to ECOG with appropriate laboratory science correlative studies. The expansion of Center facilities allows the development of new clinical prograins, the recruitment of new faculty, furthering committee involvement and clinical trial accrual.

Public Health Relevance

Johns Hopkins has an extraordinary institutional commitment to the health of the public. Through close collaboration, the Cancer Center and the School of Public Health advance the study of not only cancer treatments, but also the early detection, screening, prevention of cancer, and its effect on financial stability and quality of life, thus encompassing the overall impact of cancer on the lives of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA016116-40
Application #
8468646
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2014-02-28
Budget Start
2013-05-01
Budget End
2014-02-28
Support Year
40
Fiscal Year
2013
Total Cost
$227,541
Indirect Cost
$79,896
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Psyrri, Amanda; Lee, Ju-Whei; Pectasides, Eirini et al. (2014) Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res 20:3023-32
Brahmer, Julie R; Dahlberg, Suzanne E; Gray, Robert J et al. (2011) Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459 J Thorac Oncol 6:103-8
Litzow, Mark R; Othus, Megan; Cripe, Larry D et al. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148:217-25
Aisner, Seena C; Dahlberg, Suzanne; Hameed, Meera R et al. (2010) Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Onc J Thorac Oncol 5:885-92
Chung, Christine H; Seeley, Erin H; Roder, Heinrich et al. (2010) Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 19:358-65
Horning, Sandra J; Juweid, Malik E; Schoder, Heiko et al. (2010) Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 115:775-7; quiz 918
Wolff, Antonio C; Wang, Molin; Li, Hailun et al. (2010) Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 121:111-20
Hughes, Lorie L; Wang, Molin; Page, David L et al. (2009) Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-24
Koch, Wayne M; Ridge, John A; Forastiere, Arlene et al. (2009) Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg 135:851-8

Showing the most recent 10 out of 68 publications